PMID- 35712787
OWN - NLM
STAT- MEDLINE
DCOM- 20221006
LR  - 20221116
IS  - 1878-0261 (Electronic)
IS  - 1574-7891 (Print)
IS  - 1574-7891 (Linking)
VI  - 16
IP  - 19
DP  - 2022 Oct
TI  - Prostate cancer disease recurrence after radical prostatectomy is associated with 
      HLA type and local cytomegalovirus immunity.
PG  - 3452-3464
LID - 10.1002/1878-0261.13273 [doi]
AB  - Prostate cancer is a heterogeneous disease with a need for new prognostic 
      biomarkers. Human leukocyte antigen (HLA) genes are highly polymorphic genes 
      central to antigen presentation to T-cells. Two alleles, HLA-A*02:01 and 
      HLA-A*24:02, have been associated with prognosis in patients diagnosed with de 
      novo metastatic prostate cancer. We leveraged the next-generation sequenced 
      cohorts CPC-GENE and TCGA-PRAD to examine HLA alleles, antiviral T-cell receptors 
      and prostate cancer disease recurrence after prostatectomy. Carrying HLA-A*02:01 
      (111/229; 48% of patients) was independently associated with disease recurrence 
      in patients with low-intermediate risk prostate cancer. HLA-A*11 (carried by 
      42/441; 10% of patients) was independently associated with rapid disease 
      recurrence in patients with high-risk prostate cancer. Moreover, HLA-A*02:01 
      carriers in which anti-cytomegalovirus T-cell receptors (CMV-TCR) were identified 
      in tumors (13/144; 10% of all patients in the cohort) had a higher risk of 
      disease recurrence than CMV-TCR-negative patients. These findings suggest that 
      HLA-type and CMV immunity may be valuable biomarkers for prostate cancer 
      progression.
CI  - (c) 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on 
      behalf of Federation of European Biochemical Societies.
FAU - Classon, Johanna
AU  - Classon J
AUID- ORCID: 0000-0003-0392-7605
AD  - Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Zamboni, Margherita
AU  - Zamboni M
AD  - Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Engblom, Camilla
AU  - Engblom C
AD  - Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Alkass, Kanar
AU  - Alkass K
AD  - Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden.
FAU - Mantovani, Giulia
AU  - Mantovani G
AUID- ORCID: 0000-0002-5307-165X
AD  - Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Pou, Christian
AU  - Pou C
AD  - Science for Life Laboratory, Department of Women's and Children's Health, 
      Karolinska Institutet, Stockholm, Sweden.
FAU - Nkulikiyimfura, Dieudonne
AU  - Nkulikiyimfura D
AD  - Science for Life Laboratory, Department of Women's and Children's Health, 
      Karolinska Institutet, Stockholm, Sweden.
FAU - Brodin, Petter
AU  - Brodin P
AD  - Science for Life Laboratory, Department of Women's and Children's Health, 
      Karolinska Institutet, Stockholm, Sweden.
FAU - Druid, Henrik
AU  - Druid H
AD  - Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden.
FAU - Mold, Jeff
AU  - Mold J
AD  - Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Frisen, Jonas
AU  - Frisen J
AD  - Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 
      Sweden.
LA  - eng
SI  - RefSeq/NC_006273.2
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220831
PL  - United States
TA  - Mol Oncol
JT  - Molecular oncology
JID - 101308230
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA-A Antigens)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Antiviral Agents
MH  - Cytomegalovirus
MH  - *Cytomegalovirus Infections/genetics
MH  - HLA-A Antigens
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/genetics
MH  - Prostatectomy
MH  - *Prostatic Neoplasms/genetics/surgery
MH  - Receptors, Antigen, T-Cell/genetics
PMC - PMC9533687
OTO - NOTNLM
OT  - HLA-alleles
OT  - T-cells
OT  - antiviral protection
OT  - cytomegalovirus (CMV)
OT  - prognosis
OT  - prostate cancer
COIS- MZ, JF, CE and JM are consultants to 10x Genomics.
EDAT- 2022/06/18 06:00
MHDA- 2022/10/07 06:00
PMCR- 2022/10/01
CRDT- 2022/06/17 02:52
PHST- 2022/05/31 00:00 [revised]
PHST- 2022/03/09 00:00 [received]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/10/07 06:00 [medline]
PHST- 2022/06/17 02:52 [entrez]
PHST- 2022/10/01 00:00 [pmc-release]
AID - MOL213273 [pii]
AID - 10.1002/1878-0261.13273 [doi]
PST - ppublish
SO  - Mol Oncol. 2022 Oct;16(19):3452-3464. doi: 10.1002/1878-0261.13273. Epub 2022 Aug 
      31.